Should We Incorporate Urinary Tumour DNA Status in Treatment Decisions for Patients with Non–muscle-invasive Bladder Cancer? In this issue of European Urology, St-Laurent et al [1] report that detectable levels of urinary tumour DNA (utDNA) are highly predictive of recurrence in patients with bacillus Calmette-Guérin (BCG)-unresponsive non–muscle-invasive bladder cancer (NMIBC) treated with atezolizumab in SWOG S1605, a single-arm phase 2 trial. Just as the presence of detectable circulating tumour DNA (ctDNA) before, during, or after treatment for patients with muscle-invasive bladder cancer (MIBC) has important prognostic implications [2], detection of utDNA before, during, or after treatment of NMIBC may also be prognostic.
https://www.europeanurology.co....m/article/S0302-2838